Umoja wa Ulaya - Kijerumani - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastische mittel - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

baxter holding b.v. (8182259) - pulver zur herstellung einer injektions- /infusionslösung - 500 mg

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

dr. falk pharma gmbh (3076297) - zäpfchen - 4 mg

Umoja wa Ulaya - Kijerumani - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunsuppressiva - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

hikma pharma gmbh (3220831) - paclitaxel - konzentrat zur herstellung einer infusionslösung - paclitaxel (26509) 6 milligramm

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

pfizer pharma gmbh (8075658) - epirubicinhydrochlorid - pulver zur herstellung einer injektionslösung - teil 1 - pulver zur herstellung einer injektionslösung; epirubicinhydrochlorid (22966) 50 milligramm

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

astellas pharma gmbh (8083037) - bendamustin - pulver zur herstellung einer infusionslösung - bendamustin (26567) 2,5 milligramm

Ujerumani - Kijerumani - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

actavis group ptc ehf. (8092378) - carboplatin - konzentrat zur herstellung einer infusionslösung - teil 1 - konzentrat zur herstellung einer infusionslösung; carboplatin (23168) 10 milligramm

Umoja wa Ulaya - Kijerumani - EMA (European Medicines Agency)

bayer ag - riociguat - bluthochdruck, lungen - antihypertensiva für die pulmonale arterielle hypertonie - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. die wirksamkeit wurde in einer pah-population einschließlich ätiologien einer idiopathischen oder erblich bedingte pah oder pah assoziiert mit bindegewebserkrankungen. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Umoja wa Ulaya - Kijerumani - EMA (European Medicines Agency)

teva b.v. - zoledronsäure - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - medikamente zur behandlung von knochenerkrankungen - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. behandlung von morbus paget des knochens bei erwachsenen.